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In Brief
The metabolic-inflammatory crosstalk plays a key role in host defense against pathogens and inflammation. Guo and colleagues demonstrate that SCAP-SREBP2 complex integrates NLRP3 inflammasome activation and cholesterol biosynthetic signaling during inflammation.
INTRODUCTION
The immune and metabolic systems are highly integrated with one another, and this is critical for immune cells to fulfill their functions. A hallmark of pro-inflammatory macrophages is the increased anabolic demand in response to pathogen-or damage-associated molecular patterns (PAMPs or DAMPs) (O'Neill et al., 2016; Pearce and Pearce, 2013) . The NLRP3 inflammasome is a molecular platform that modulates innate immune functions via the maturation of caspase-1 and via the cleavage of cytokine substrates such as pro-interleukin (IL)-1b and pro-IL-18 (Rathinam and Fitzgerald, 2016) . Recent studies have implicated several cellular metabolites and metabolic enzymes, traditionally linked to metabolism but not immunity, in modulation of NLRP3 inflammasome activation (Pró chnicki and Latz, 2017) .
Cholesterol is an essential lipid involved in diverse biological processes (Tall and Yvan-Charvet, 2015) . Excess cholesterol can form cholesterol crystals, which directly activate the NLRP3 inflammasome and underlie the pathogenesis of atherosclerosis (Duewell et al., 2010) . Cholesterol accumulation in dendritic cells accelerates the development of autoimmunity via the NLRP3 inflammasome, possibly at the transcriptional level (Ito et al., 2016; Westerterp et al., 2017) . However, the molecular mechanisms that directly link cholesterol metabolic signaling and NLRP3 inflammasome activation remain poorly defined.
The sterol regulatory element-binding proteins (SREBPs) are master regulators of lipid homeostasis (Goldstein et al., 2006) . Mammals have two SREBP-encoding genes that express three SREBPs: SREBP1a, SREBP1c, and SREBP2. SREBP2 principally regulates genes involved in cholesterol metabolism, whereas genes involved in fatty-acid metabolism are preferentially regulated by SREBP1. They are synthesized as inactive precursors localized to the endoplasmic reticulum (ER) bound to SREBP cleavage-activating protein (SCAP). SCAP escorts SREBPs via coat protein complex II (COPII) vesicles to the Golgi apparatus where two steps of proteolytic cleavage mediated by Site-1 protease (S1P) and Site-2 protease (S2P) releases the N terminus of SREBP protein and allows its entry into the nucleus (Goldstein et al., 2006 ).
In the current study, we found that SCAP-SREBP2 promoted NLRP3 inflammasome activation, which was mainly dependent on its ER-to-Golgi translocation, rather than by affecting cholesterol homeostasis. By inhibiting this translocation, synthetic SCAP-SREBP2 inhibitors and endogenous sterols including cholesterol and 25-HC suppressed NLRP3 inflammasome activation both in vitro and in vivo. In contrast, cholesterol depletion or statins promoted NLRP3 inflammasome activation by enforcing this process. Collectively, we unveil an important role of SCAP-SREBP2 that is directly used by NLRP3 for inflammasome activation, thus suggesting an intimate metabolic-inflammatory crosstalk in pro-inflammatory macrophages.
RESULTS

NLRP3 Inflammasome Activation Couples SCAP ER-toGolgi Translocation and SREBP2 Maturation
Upon nigericin stimulation in lipopolysaccharide (LPS)-primed THP1 macrophages, we found that the SREBP2 inactive precursor (pre-SREBP2) was clearly proteolytically processed to the N-terminal mature form (n-SREBP2) ( Figure 1A ). To determine whether this nigericin-induced SREBP2 processing occurred via the well-established SCAP-, S1P-, and S2P-dependent pathway, we used several synthetic inhibitors and endogenous sterols targeting this pathway ( Figure 1B ). Betulin, a small molecule that specifically inhibits SCAP-SREBP2 activation by interacting with SCAP (Tang et al., 2011) , suppressed this nigericininduced cleavage of SREBP2 ( Figure 1C ). Desmosterol binds to SCAP and prevents it from interacting with COPII proteins, which results in the retention of SCAP-SREBP2 in the ER. In contrast, the oxysterol 25-HC binds to the ER-retention proteins Insig1 and/or Insig2, thereby causing SCAP-SREBP2 to also be retained in the ER (Spann and Glass, 2013) . We found that either desmosterol or 25-HC suppressed this nigericin-induced SREBP2 maturation ( Figure 1D ). Furthermore, S1P inhibition by PF-429242 or AEBSF and S2P inhibition by 1,10-phenanthroline (Feng et al., 2007; Okada et al., 2003; Shao and Espenshade, 2014) were capable of suppressing this nigericin-induced SREBP2 maturation ( Figure 1E ). Altogether, these findings suggested that this SREBP2 maturation occurring during NLRP3 inflammasome activation also relied on SCAP and the sequential processing by S1P and S2P. In contrast, treatment with the caspase-1 inhibitor z-YVAD-fmk or the pan-caspase inhibitor z-VAD-fmk had limited effects on this SREBP2 maturation (Figure 1F) . To further strengthen these results in primary macrophages, we measured the mRNA expression of SREBP2 target genes as indicative of SREBP2 maturation, including Srebf2 which is a direct target of itself (Sato et al., 1996) . Our data showed that the five measured genes involved in cholesterol metabolism, Srebf2, Hmgcr, Ldlr, Hmgcs1, and Insig1, were modestly increased in LPS-primed bone marrow-derived macrophages (BMDMs) and then further enhanced upon ATP or nigericin stimulation (Figures 1G and S1A) . Similar results were obtained in LPS-primed mouse peritoneal macrophages upon ATP stimulation ( Figure 1H ). In contrast, the caspase-1 inhibitor VX765 had no effect on the upregulation of these SREBP2 target genes ( Figure S1A ). Consistently, SCAP or S1P deficiency in BMDMs blocked this upregulation of SREBP2 target genes, whereas NLRP3, ASC, or Caspase-1 deficiency showed less effect on that, further suggesting that SREBP2 maturation may not depend on NLRP3 inflammasome activation in macrophages ( Figure 1I ). In contrast, the six measured genes involved in fatty-acid metabolism, Srebf1, Acly, Acaca, Fasn, Acss2, and Gpam, were less affected during NLRP3 inflammasome activation in BMDMs ( Figure S1B ). In addition, Scap and cholesterol efflux genes including Abca1 and Abcg5 were largely unchanged ( Figure S1C ).
Taken together, our data demonstrate that activation of the NLRP3 inflammasome is coupled with SCAP ER-to-Golgi translocation and SREBP2 maturation.
Inhibition of SCAP-SREBP2 ER-to-Golgi Translocation Impairs NLRP3 Inflammasome Activation We next examined the role of SCAP-SREBP2 in NLRP3 inflammasome activation by acute inhibition of its ER-to-Golgi translocation ( Figure 2A ). Betulin, which inhibits SCAP-SREBP2 ER-to-Golgi translocation by interacting with SCAP, markedly suppressed ATP-induced caspase-1 maturation and IL-1b or IL-18 secretion in a dose-dependent manner (Figures 2B and 2C) . Apart from ATP, betulin also inhibited the caspase-1 maturation and IL-1b secretion triggered by the NLRP3 agonists nigericin, monosodium urate crystals (MSU), and alum ( Figures  2D and 2E ). In addition, ASC (apoptosis-associated speck-like protein containing a CARD) nucleation-induced oligomerization and ASC-speck formation were also inhibited by betulin ( Figures  2F and 2G ). In contrast, betulin had no effect on activation of the AIM2 and NLRC4 inflammasomes, which are triggered by poly(dA:dT) transfection and Salmonella typhimurium infection, respectively (Figures 2H and 2I) . Another selective synthetic inhibitor of SCAP-SREBP2 ER-to-Golgi translocation via binding to SCAP, fatostatin (Kamisuki et al., 2009) , similarly inhibited activation of the NLRP3 inflammasome (Figures 2J and 2K) . We reasoned that the suppressed NLRP3 inflammasome activity might be explained by a perturbation in cellular cholesterol homeostasis. However, the cellular cholesterol amounts and viability remained unchanged after treatment of these inhibitors (Figures S2A and S2B) . We also examined these inhibitory effects of betulin and fatostatin on NLRP3 inflammasome activation in human monocyte-derived macrophages and found similar results ( Figures S2C and S2D) .
We next investigated this regulation of the NLRP3 inflammasome using two endogenous sterols that directly inhibit SCAP-SREBP2 ER-to-Golgi translocation: 25-HC and cholesterol itself. We found that 25-HC dose dependently repressed ATP-or (legend continued on next page)
nigericin-induced caspase-1 maturation, IL-1b production, ASC oligomerization, and ASC-speck formation ( Figures 2L, 2M , S2E, and S2F). Although cholesterol crystal has been shown to promote inflammasome activation and atherogenesis (Duewell et al., 2010; Sheedy et al., 2013) , under physiological conditions, the ER contains a delicate feedback system that senses the excess cholesterol to inactivate SCAP-SREBP2 translocation and thus maintains the intracellular cholesterol within narrow limits (Goldstein et al., 2006; Radhakrishnan et al., 2008; Spann and Glass, 2013) . As predicted, acute treatment with 20-60 mg/mL methyl-b-cyclodextrin (MCD)-cholesterol during activation stage of the NLRP3 inflammasome, concentrations typically used to inhibit SCAP-SREBP2 ER-to-Golgi translocation, clearly suppressed, rather than promoted, NLRP3 inflammasome activation in a dose-dependent manner ( Figures 2N  and 2O ). Moreover, 60 mg/mL cholesterol did not directly activate the NLRP3 inflammasome in LPS-primed BMDMs as a danger signal like crystalline cholesterol ( Figures 2N and 2O ). Importantly, this inhibitory effect of cholesterol on NLRP3 inflammasome activation was prompt ( Figure S2G ), which is in line with the report that MCD-cholesterol is transferred rapidly from the plasma membrane to the ER by vesicular or non-vesicular carriers (Prinz, 2007) . Furthermore, we also examined this regulatory effect of cholesterol on NLRP3 inflammasome with liposomal-cholesterol and obtained similar results ( Figure S2H ). SCAP-SREBP2 plays a well-defined role in the transcriptional regulation of enzymes involved in the cholesterol-biosynthetic mevalonate pathway. However, consistent with the previous studies showing that blockade of the mevalonate pathway by statins enhances NLRP3 inflammasome activation (Pró chnicki and Latz, 2017; Spann and Glass, 2013) , NB-598 targeting downstream squalene epoxidase also slightly increased IL-1b production ( Figures S2I and S2J ). Taken together, our results suggest a role of SCAP-SREBP2 ER-to-Golgi translocation in activation of the NLRP3 inflammasome.
SCAP-SREBP2 Complex Is Required for Optimal NLRP3 Inflammasome Activation
We next adopted multiple genetic strategies to investigate the role of SCAP-SREBP2 in NLRP3 inflammasome activation. First, silencing of Scap (encoding SCAP) or Srebf2 (encoding SREBP2) by small-interfering RNAs (siRNAs) blocked optimal NLRP3 inflammasome activation without affecting TNF-a production in peritoneal macrophages ( Figures 3A and 3B ). Second, we generated J774.1 and THP1 macrophages stably expressing shRNAs targeting Scap and SREBF2, respectively. Similarly, J774.1-SCAP-shRNA and THP1-SREBP2-shRNA macrophages showed greatly impaired NLRP3 inflammasome activity ( Figures  S3A-S3E ). In contrast, TNF-a production and NLRC4 inflammasome activation remained unaffected in these cells ( Figures  S3F-S3H ). In line with a previous study showing that SCAP deficiency in BMDMs had limited effect on total amounts of lipids including cholesterol (York et al., 2015) , these stable Scapsilenced macrophages showed minimally affected cellular cholesterol amounts ( Figure S3I ), suggesting that SCAP may control NLRP3 inflammasome activation without affecting cellular cholesterol amounts.
We also confirmed these observations with macrophagespecific deletion of SCAP using the Lyz2-cre model (Lyz2-creScap f/f ). As expected, BMDMs from Lyz2-cre-Scap f/f mice had impaired NLRP3 inflammasome activation triggered by different NLRP3 agonists compared with control mice (Figures 3C-3E) . Moreover, compared with wild-type mice, the remaining NLRP3 inflammasome activity in BMDMs from Lyz2-cre-Scap f/f mice caused by the residual SCAP expression showed a similar kinetic response upon ATP stimulation ( Figure 3D ), suggesting that SCAP deficiency may not affect response sensitivity of the NLRP3 inflammasome. In contrast, TNF-a production was unaffected in the absence of SCAP ( Figure 3E ). To further examine whether any potential changes in cholesterol homeostasis contribute to this suppressed NLRP3 activity caused by SCAP deficiency, we supplemented different concentrations of MCDcholesterol in these macrophages. In line with the results that cholesterol suppressed NLRP3 inflammasome activation (Figures 2O and S2F) , supplementation of MCD-cholesterol suppressed, rather than restored, IL-1b production with a similar kinetic pattern in both wild-type and SCAP-deficient BMDMs ( Figure 3F ). These results together suggest that SCAP may play a direct role in NLRP3 inflammasome activation rather than change cholesterol homeostasis.
Previous studies have demonstrated that overexpression of SCAP or SREBP2 leads to spontaneous SCAP-SREBP2 ER-to-Golgi translocation (Sakai et al., 1998) . Consistently, stably transfected THP1 macrophages overexpressing SCAP or SREBP2 showed increased NLRP3 inflammasome activity . A similar result was also obtained in immortalized BMDMs stably overexpressing SCAP ( Figure S3J ). To further confirm that this promoting effect of SCAP on the NLRP3 inflammasome occurs at the activation stage, we reconstituted NLRP3 inflammasomes in HEK293T cells without expression of pro-IL-1b. Notably, overexpression of SCAP promoted nigericininduced caspase-1 maturation ( Figure 3K ). Besides overexpressing their components, we further assessed the effect of SCAP-SREBP2 on the NLRP3 inflammasome by using a ''SCAP-SREBP2 activating medium'' which constitutively transports SCAP-SREBP2 from the ER to the Golgi apparatus caused by the sterol depletion (Goldstein et al., 2006) . We found that this medium enhanced nigericin-induced caspase-1 maturation as well as IL-1b and IL-18 secretion compared with the control medium ( Figures 3L and 3M ), while the production of TNF-a was less affected ( Figure 3M ). More importantly, without an NLRP3 agonist, SCAP-SREBP2 activating medium alone promoted the maturation of IL-1b ( Figures 3M and S3K ). In addition, we induced acute SCAP-SREBP2 ER-to-Golgi translocation by (legend continued on next page) sterol extraction with methyl-b-cyclodextrin (Goldstein et al., 2006; Gurcel et al., 2006) . As expected, ATP-induced IL-1b production was augmented ( Figure S3L ). Similarly, MCD alone spontaneously triggered the maturation of IL-1b in LPS-primed macrophages, and this effect was impeded by inhibiting SCAP-SREBP2 translocation with 25-HC ( Figure S3L ). These results together suggest that enforced cholesterol biosynthetic signaling in macrophages promotes activation of the NLRP3 inflammasome.
Optimal NLRP3 Inflammasome Activation Requires Golgi S1P-but Not S2P-Mediated SREBP2 Cleavage To address the role of S1P-and S2P-mediated two-step cleavage in NLRP3 inflammasome activation, we first silenced the expression of S1P and S2P with siRNAs targeting Mbtps1 (encoding S1P) and Mbtps2 (encoding S2P) in peritoneal macrophages ( Figures S4A-S4C ). Our results revealed that specific siRNA-mediated reduction of S1P but not S2P resulted in marked suppression of NLRP3 inflammasome activation S4D, and S4E) . These results are in line with the report that the release of SCAP from the Golgi depends on the cleavage of SREBP protein by S1P but not S2P (Shao and Espenshade, 2014) , suggesting a requirement of SCAP release from the Golgi for optimal NLRP3 inflammasome activation. We next generated mice deficient in S1P in macrophages (Lyz2-cre-Mbtps1 f/f ) and found that the S1P-deficient BMDMs had greatly impaired NLRP3 inflammasome activity triggered by different NLRP3 agonists (Figures 4E, 4F, and S4F). Consistently, supplementation of different concentrations of cholesterol did not restore the decreased NLRP3 inflammasome activity in S1P-deficient BMDMs, but rather suppressed its residual NLRP3 inflammasome activity in a similar kinetic pattern to wild-type BMDMs ( Figure 4G ). In addition, we investigated the involvement of S1P in NLRP3 inflammasome activation using PF-429242 and AEBSF, two S1P inhibitors that do not affect S2P activity (Okada et al., 2003; Shao and Espenshade, 2014) . Our results revealed that acute treatment of either AEBSF or PF-429242 greatly suppressed the NLRP3 inflammasome activity ( Figures 4H-4J ), without affecting cellular cholesterol amounts and viability (Figures S2A and S2B) . Brefeldin A (BFA), which causes the Golgi to collapse into the ER and results in constitutive processing of SREBP2 in the ER by relocating S1P to the ER (DeBose-Boyd et al., 1999), spontaneously induced IL-1b secretion without an NLRP3 agonist ( Figures 4K and 4L ). Importantly, this secretion was suppressed by S1P inhibition with AEBSF ( Figures 4K and 4L ), suggesting that enforced S1P-mediated cleavage of SREBP2 promoted NLRP3 inflammasome activation. In contrast, the production of TNF-a was not affected in these experiments (Figures 4K and 4L) . In addition to BFA, we retrovirally transduced Lyz2-cre-Scap f/f BMDMs with a mutant form of S1P that contains an ER retention and retrieval signal, Lys-Asp-Glu-Leu (KDEL). This also causes relocation of S1P from the Golgi to the ER and bypasses the SCAP requirement for SREBP2 cleavage (DeBose-Boyd et al., 1999) . Compared with the empty vector, S1P-KDEL enhanced NLRP3 inflammasome activation but not TNF-a production in Lyz2-cre-Scap f/f BMDMs, while the inactive S1P-KDEL-S414A mutant had no effect ( Figures 4M and S4G ). Together, these results suggest that S1P-mediated SREBP2 cleavage promotes NLRP3 inflammasome activation.
NLRP3 Associates with SCAP and SREBP2 via the NACHT Domain
The requirement of SCAP-SREBP2 for optimal NLRP3 inflammasome activation prompted us to investigate the possibility that NLRP3 associates with this complex. Co-immunoprecipitation analysis in LPS-primed BMDMs and THP1 macrophages stably expressing V5-SCAP revealed the association of NLRP3 with SCAP upon ATP and nigericin stimulation (Figures 5A and 5B) . Similarly, NLRP3 also associated with SREBP2 in LPS-primed BMDMs and THP1 macrophages stably expressing Flag-SREBP2, and this was further enhanced by stimulation with an NLRP3 agonist ( Figures 5C and 5D ). To further confirm these interactions, we performed GST pull-down assay and found the direct interaction of NLRP3 with either SCAP or SREBP2 ( Figures  5E and 5F ). To further delineate the association of NLRP3 with the SCAP-SREBP2 complex, we introduced various truncated mutants of these proteins according to their domain structures into HEK293T cells ( Figure 5G ). As predicted, NLRP3 associated with the SCAP WD40-repeat domain but not the N-terminal transmembrane domain, mainly through its NACHT domain ( Figures 5H, 5I , S5A, and S5B). In addition, the NLRP3 NACHT domain and the SREBP2 C-terminal regulatory domain were mainly required for the association between NLRP3 and SREBP2 ( Figures 5J, 5K , S5C, and S5D). These results presented thus far support a scenario in which NLRP3 associates with both SCAP and SREBP2, so we hypothesized that a ternary complex might be formed with these three proteins. To test this hypothesis, we performed co-immunoprecipitation experiments in HEK293T cells transfected with V5-SCAP, HA-NLRP3, and Flag-SREBP2. Immunoprecipitation of SREBP2 pulled down both SCAP and NLRP3, while immunoprecipitation of SCAP pulled down both NLRP3 and SREBP2 ( Figure 5L ). Furthermore, we performed a two-step co-immunoprecipitation assay in these cells. As expected, NLRP3 was present in the final immunoprecipitate but not in the control samples ( Figure 5M ). In contrast, SCAP and SREBP2 did not associate with other essential components of the NLRP3 inflammasome, including NEK7 and ASC ( Figures S5E and S5F ). Taken together, our results suggest that SCAP-SREBP2 promotes NLRP3 inflammasome activation by forming a ternary complex with NLRP3.
NLRP3 Associates with SCAP for Its Golgi Translocation during NLRP3 Inflammasome Activation
Considering its well-established escort function and association with NLRP3, we hypothesized that SCAP might also be (L and M) Immunoblotting (L) and ELISA (M) of supernatants (SN) and cell extracts (Lysate) from BMDMs cultured for 16 hr in control medium or SCAP-SREBP2 activating medium with 10% lipoprotein-deficient serum (LPDS), 10 mM lovastatin, and 50 mM mevalonate primed with LPS for 4 hr, and then stimulated with nigericin. *p < 0.05, **p < 0.01, ***p < 0.001. Values are mean ± SD. Data are representative of three independent experiments. See also Figure S3 . involved in the translocation of NLRP3 required for its optimal activation (Pró chnicki and Latz, 2017; Rathinam and Fitzgerald, 2016) . In LPS-primed BMDMs, NLRP3 was partially co-localized with SCAP or SREBP2 in the perinuclear region, and this was markedly enhanced by ATP stimulation (Figures 6A and  6B ). Furthermore, we performed in situ proximity ligation assays, which are suitable for quantitative studies of the spatial proximity of two molecules. In line with the confocal analysis, we found that LPS caused spatial approximation of NLRP3 to SCAP or SREBP2 in BMDMs, and this was markedly enhanced by ATP stimulation (Figures 6C and 6D ). HEK293T cells expressing NLRP3 with more physiological amounts can be used to investigate the subcellular translocation of NLRP3 during inflammasome activation ( Figure S6A ; Subramanian et al., 2013) . As found in BMDMs, a small portion of resting NLRP3 was in close proximity to SCAP in the perinuclear region, which was markedly promoted upon nigericin stimulation ( Figure S6B ). The Golgi serves as a critical platform for SREBP2 processing, but its contribution to the NLRP3 inflammasome remains largely unknown. To examine more precisely the involvement of NLRP3 translocation in the dynamics of Golgi and mitochondria during inflammasome activation, we performed super-resolution and 3D-structured illumination microscopy (SIM) imaging in BMDMs. We observed that ATP stimulation re-localized NLRP3 to regions very close to the Golgi membranes ( Figure 6E ; Videos S2 and S3). In the resting state, the mitochondria were string-like in shape ( Figure 6E ; Video S1). In contrast, dot-like mitochondrial clustering, representing damaged mitochondria and thought to provide several factors necessary for NLRP3 activation (Pró chnicki and Latz, 2017; Zhou et al., 2011) , was observed adjacent to the Golgi membranes with NLRP3 ( Figure 6E ; Videos S2 and S3), in line with a very recent study showing that activation of the NLRP3 inflammasome induces mitochondrial clustering around the Golgi (Zhang et al., 2017) . To confirm these observations, we studied subcellular fractions from THP1-V5-SCAP macrophages. Notably, NLRP3 was substantially detected in the Golgi fraction ( Figure 6F) , and more importantly, SCAP and NLRP3 were both detected in the mitochondrial fraction in a roughly similar manner upon nigericin stimulation (Figure 6G) . Last, using super-resolution and 3D-SIM, we observed that a portion of NLRP3 was localized close to both SCAP and the COPII protein Sec23A (Figure S6C ), suggesting that the COPII-coated vesicles may also be used by SCAP for NLRP3 transport during inflammasome activation. Altogether, we hypothesized that the interface between Golgi and mitochondrial clustering may provide a platform for NLRP3 inflammasome activation.
SCAP-SREBP2 Promotes NLRP3 Inflammasome Activation In Vivo
We finally set out to determine whether SCAP-SREBP2 promotes NLRP3 inflammasome activation in vivo. First, when challenged with LPS, Lyz2-cre-Scap f/f mice showed significantly reduced serum IL-1b and IL-18 but unaffected TNF-a production ( Figure 7A ). Moreover, SCAP deficiency in macrophages significantly increased the survival of mice challenged with LPS (Figure S7A) . Second, betulin or fatostatin treatment significantly reduced LPS-induced serum IL-1b and IL-18 production, similar to the reduction seen in Lyz2-cre-Scap f/f mice ( Figures 7B and  7C) . Importantly, there was little additional decrease in IL-1b and IL-18 production when we treated Lyz2-cre-Scap f/f mice with betulin or fatostatin, suggesting that SCAP-SREBP2 is the main target of betulin or fatostatin in this sepsis model ( Figures  7B and 7C ). In contrast, TNF-a production was little affected ( Figures 7B and 7C ). Third, in agreement with the results in vitro, 25-HC administration resulted in a substantial decrease of LPS-induced serum IL-1b but not TNF-a ( Figure 7D ). Similarly, this inhibitory effect of 25-HC was clearly blunted in Lyz2-creScap f/f mice ( Figure 7D ). We next addressed the role of SCAP-SREBP2 in NLRP3 inflammasome activation in vivo using a model of alum-induced peritonitis. As expected, IL-1b secretion in the lavage fluid was impaired in Lyz2-cre-Scap f/f mice. Moreover, the peritoneal exudate cells and neutrophils recruited upon alum challenge were significantly fewer in these mice ( Figure 7E ). Consistently, 25-HC treatment also suppressed the alum-induced peritonitis in vivo ( Figure S7B ), suggesting an immunomodulatory effect of this endogenous sterol during inflammatory responses in vivo, at least in the models of sepsis and peritonitis we explored. Statins are widely used for lowering cholesterol by targeting HMG CoA reductase. However, their potent action of blocking de novo cholesterol synthesis also enhances SCAP-SREBP2 activation in vivo (Matsuda et al., 2001; Spann and Glass, 2013) . Our results revealed that both in the sepsis and peritonitis models, mice fed a diet supplemented with 0.2% lovastatin for 4 days showed markedly higher IL-1b production than control mice ( Figures 7F and 7G) , while the TNF-a production remained unaffected ( Figure 7F ). However, lovastatin administration suppressed, rather than promoting, IL-1b production in Lyz2-creScap f/f mice, suggesting that the complex effects of statins on IL-1b production depend on the activity of SCAP-SREBP2 ( Figure S7C ). In addition, this promoting effect of lovastatin on IL-1b production was recapitulated in human peripheral blood mononuclear cells (PBMCs). Importantly, betulin and fatostatin suppressed this effect, suggesting a potential promoting action of statins on IL-1b production via SCAP-SREBP2 activation ( Figure S7D ). Last, gain-of-function mutations in the Nlrp3 gene result in its activation or predisposition for activation and are associated with the cryopyrin-associated periodic fever syndromes (CAPS) (Masters et al., 2009) . We retrovirally transduced the BMDMs from Nlrp3
A350VneoR mice (corresponding to CAPS patient NLRP3 A352V ) with Cre to induce NLRP3 A350V activation (Brydges et al., 2009) . We found that this NLRP3 A350V -mediated IL-1b production was greatly suppressed by betulin, fatostatin, or AEBSF ( Figure 7H ). Similarly, these inhibitors suppressed another CAPS-associated NLRP3
R258W
-mediated IL-1b production (Figure S7E) . Collectively, these results indicate that SCAP-SREBP2 activation promotes NLRP3 inflammasome activity in vivo and suggest SCAP-SREBP2 as a potential target for NLRP3-related diseases.
DISCUSSION
In this study, we established a previously unknown and unexpected role for the SCAP-SREBP2 complex in pro-inflammatory macrophages as an important signaling hub integrating cholesterol metabolism and innate immunity. In line with our result that enforced activation of cholesterol biosynthetic signaling promoted spontaneous NLRP3 inflammasome activation, a central facet of the type I interferon-mediated suppressive effect on immunity is downregulation of inflammasome activity (Guarda et al., 2011 ) and its signaling is spontaneously activated by limiting cholesterol synthetic flux (York et al., 2015) . Thus, these results suggested that cholesterol synthetic flux in immune cells may be part of the metabolic-inflammatory circuit to ensure that any changes in the activity of one can be sensed by the other.
Although cholesterol biosynthetic signaling is coupled to NLRP3 inflammasome activation, the promoting effect of SCAP-SREBP2 on NLRP3 inflammasome activation was independent of the transcriptional activity of n-SREBP2 controlling the cholesterol biosynthetic genes involved in the mevalonate pathway. Instead, our study indicates that statins potentially promote NLRP3 inflammasome activation and IL-1b production via enhancing SCAP-SREBP2 activation. Statins are widely used to lower cholesterol in the blood, but they have also been associated with increased risk of additional-onset diabetes and myopathy (Sattar et al., 2010) . Therefore, it will be worthwhile to examine their effects on inflammasome activation in human subjects; this might foster additional therapeutic and diagnostic strategies for statin-induced risk of disease.
There are discrepancies in the roles of cholesterol and its related metabolites in NLRP3 inflammasome activation. Besides the cholesterol crystals (Duewell et al., 2010) , non-crystalline cholesterol at high concentrations is also reported to directly trigger activation of the inflammasomes, possibly by impairing mitochondrial function (Dang et al., 2017; Youm et al., 2012) . In contrast, we found that cholesterol and 25-HC had potent inhibitory effects on activation stage of the NLRP3 inflammasome. In addition, MCD-induced cholesterol depletion promoted NLRP3 inflammasome activation, in line with the report that reduced plasma membrane cholesterol enhances NLRP3 inflammasome activation (Lordé n et al., 2017). Moreover, two recent studies have reported that cholesterol 25-hydroxylase (Ch25h) has an inhibitory effect on inflammasomes by synthesizing 25-HC from cholesterol (Dang et al., 2017; Reboldi et al., 2014) . Of note, Ch25h is induced in macrophages by type I interferons downstream of Toll-like receptor 3 (TLR3) or TLR4 activation , suggesting that this immunomodulatory effect of 25-HC might occur in a later phase of the inflammatory responses. However, a recent study also reported that 25-HC activates the NLRP3 inflammasome, leading to cerebral inflammation (Jang et al., 2016) . Taken together, these results suggest that, depending on the cell type and cellular sterol homeostasis (e.g., amount, type, crystal formation, and intracellular distribution) in different phases of inflammatory responses, cholesterol and/or sterols may directly or indirectly (for example, converted to 25-HC) exert either a positive or a negative influence on NLRP3 activation.
Our results strongly support the idea that SCAP-SREBP2 promotes NLRP3 inflammasome activation mainly in a direct manner without affecting cholesterol homeostasis. However, this raises the question of the physiological purpose of the increased cholesterol biosynthetic signaling during NLRP3 inflammasome activation, which was not addressed in this study. Recently, an increasing body of evidence has suggested that the inflammasome-mediated cytokine maturation and pyroptosis are not tightly coupled (Gaidt et al., 2016; Yan et al., 2013; Zanoni et al., 2016) . A very recent study identified a non-pyroptotic function of GSDMD for IL-1b release in living macrophages with a ''hyperactivated'' status between ''activated'' and ''pyroptotic'' status (Evavold et al., 2018) . The pyroptosis offers the benefit of a massive inflammatory response. However, the cost of pyroptosis is the loss of any necessary immunomodulatory activities. We therefore propose that the ''activated'' macrophages may have a mechanism that senses the severity of a threat to determine whether cell death is obligatory for defense. Otherwise, if secreted cytokines are capable of relieving the threat, SCAP-SREBP complex-mediated lipogenesis could preserve the integrity of the plasma membrane to promote cell survival. In line with this hypothesis, bacterial pore-forming toxins activate the inflammasome to promote caspase-1 activation in mammalian fibroblasts, which further acts on an as-yet-unknown intermediate target to induce SREBP processing for cell survival (Gurcel et al., 2006) . Our results revealed that the interface between Golgi and mitochondrial clustering may function as an important platform for NLRP3 inflammasome activation, which is in line with a very recent study reporting a similar observation (Zhang et al., 2017) . More importantly, Golgi collapse caused by brefeldin A blocked nigericin-induced and virus-induced NLRP3 inflammasome activation, suggesting an essential role of the intact Golgi apparatus in NLRP3 inflammasome activation (Ichinohe et al., 2010; Triantafilou et al., 2013; Zhang et al., 2017) . Of note, brefeldin A also blocks anterograde transport and translocates Golgi proteins, including S1P, back to the ER. We found that brefeldin A alone served as an NLRP3 agonist, and this was suppressed by S1P inhibition. These results may explain why the brefeldin A-induced NLRP3 inflammasome activation seems to be independent of ER stress and unfolded protein response (Bronner et al., 2015; Menu et al., 2012) .
In conclusion, the studies described here provide mechanistic insights into how SCAP-SREBP2 complex-mediated cholesterol biosynthetic signaling engages optimal activation of the NLRP3 inflammasome and advances our understanding of the metabolic-inflammatory circuit in pro-inflammatory macrophages.
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Detailed methods are provided in the online version of this paper and include the following: 
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Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Di Wang (diwang@zju.edu.cn). housed in a specific pathogen-free facility in the University Laboratory Animal Center. Animal experimental protocols were approved by the Review Committee of Zhejiang University School of Medicine and were in compliance with institutional guidelines.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cells
Mouse BMDMs were generated as previously described (Guo et al., 2016) . Mouse peritoneal macrophages were collected 4 days after thioglycollate (Millipore) injection. iBMDMs, immortalized mouse macrophages (kindly provided by Prof. Feng Shao of National Institute of Biological Sciences, Beijing), and J774.1 cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum and 1% penicillin and streptomycin. THP-1 cells were cultured in RPMI 1640 containing the same supplements. THP-1 cells were differentiated for 3 hr with 100 nM phorbol myristate (PMA) and re-plated. PBMCs were isolated from peripheral blood from healthy volunteers who had given informed consent. Human monocyte-derived macrophages were generated from PBMCs purified from blood using Ficoll and cultured in RPMI-1640 medium containing 10% FBS and 1% penicillin-streptomycin and human GM-CSF (20 ng/mL, Peprotech) for 7 days. For stimulation, 7 3 10 5 cells were plated in 12-well plates overnight, the medium was changed to opti-MEM the following morning, and then the cells were primed with LPS (500 ng/mL) for 4 hr. After that, the cells were stimulated with various NLRP3 activators [2 mM ATP (30 min); 10 mM nigericin (30 min); 200 mg/mL MSU (5 hr); 300 mg/mL alum (5 hr)]. For AIM2 inflammasome activation, poly(dA:dT) (1 mg/mL) was transfected using Lipofectamine 2000 (3 ml/mg DNA) following the manufacturer's protocol (Invitrogen). For NLRC4 inflammasome activation, S. typhimurium was grown overnight in Luria-Bertani broth, and BMDMs were infected for 1 hr with the salmonella culture (1:100) and then incubated for another 1 hr in the presence of gentamycin. Inhibitors were added 30 min or 1 hr before the inflammasome activators unless otherwise noted. Cell lysates and precipitated supernatants were analyzed by western blotting.
Reagents ATP, LPS from Escherichia coli 0111:B4, PMA, 25-HC, cholesterol, desmosterol, and methyl-b-cyclodextrin were from Sigma; nigericin, MSU, and poly-(dA:dT) were from Invivogen; betulin and fatostatin were from TargetMol; lovastatin, z-VAD-FMK, VX-765, nelfinavir mesylate, AEBSF, and xanthohumol were from Selleck chemicals; BFA was from Biolegend; PF429242 was from MedChem Express; alum was from Thermo Fisher Scientific; and Salmonella was a kind gift from Prof. Yongqun Zhu of Zhejiang University. The antibody against human IL-1b (12242) was from Cell Signaling; anti-IL-1b was from R&D Systems; anti-mouse caspase-1 (AG-20B-0044 and AG-20B-0042), anti-NLRP3 (AG-20B-0014), and anti-ASC (AG-25B-0006) were from Adipogen; anti-SCAP (sc-9675) was from Santa Cruz; anti-SREBP2 (ab30682), anti-S1P (ab140592), and anti-S2P (ab140594) were from Abcam; and anti-Flag (0912-1), anti-V5 (M1008-2), anti-Myc (EM31105), anti-HA (0906-1), and anti-b-actin (M1210-2) were from HuaAn biotechnology, Hangzhou, China. 
METHOD DETAILS
Reconstitution of NLRP3 Inflammasome in HEK293T cells HEK293T cells were seeded into 6-well plates at 5 3 10 5 per well in complete cell culture medium. After 24 hr, the cells were transfected with plasmids expressing Myc-pro-caspase-1 (500 ng), HA-ASC (150 ng), HA-NLRP3 (200 ng) and V5-SCAP (200 ng), using polyethylenimine. Forty-eight hours later, the cells were stimulated with nigericin for 30 min, and lysates were analyzed for the cleavage of pro-caspase-1 by western blotting.
Transfection and Co-Immunoprecipitation Briefly, constructs were transfected into HEK293T cells using Polyethylenimine. After 24 hr, the cells were collected and resuspended in lysis buffer (50 mM Tris-Cl, 5 mM EDTA pH 7.4, 150 mM NaCl, 0.5% (vol/vol) Nonidet-P40, and 10% (vol/vol) glycerol) supplemented with 1 mM PMSF, 1 mM dithiothreitol (DTT), and complete protease inhibitor cocktail. Cell lysates were immunoprecipitated with the indicated antibody (after addition of protein A/G beads) overnight at 4 C and then immunocomplexes were washed three times in lysis buffer, resolved by SDS-PAGE, and analyzed by western blotting.
For two-step co-immunoprecipitation, HEK293T cells were transfected with V5-SCAP, Flag-SREBP2, and HA-NLRP3. After 24 hr, the cells were lysed with lysis buffer, and the lysates were incubated with anti-Flag M2 beads (Sigma) for 4 hr at 4 C. The beads were washed three times with elution buffer (50 mM Tris-Cl pH 7.5, 200 mM NaCl, 0.02% (vol/vol) Nonidet-P40, and 10% (vol/vol) glycerol) supplemented with 1 mM PMSF and 1 mM DTT, and the Flag-SREBP2 protein complex was eluted with 60 mL elution buffer containing 200 mg/mL 3 3 Flag peptide (Sigma) for 1.5 hr at 4 C. Ten-microliter eluents were mixed with 2 3 SDS loading as the first immunoprecipitation elution for western blotting. For the second immunoprecipitation, 450 mL lysis buffer containing anti-V5 antibody with protein A/G beads was mixed with the remaining 50 mL eluent from the first immunoprecipitation, incubated with rotation overnight at 4 C, and then the immunocomplexes were washed three times in lysis buffer, resolved by SDS-PAGE, and analyzed by western blotting.
ASC Oligomerization and ASC Speck Formation
BMDMs were plated in six-well plates (2 3 10 6 cells per well) and then stimulated with 500 ng/mL LPS for 4 hr the following day. Cells were treated with 10 mM nigericin for 45 min in the presence of the indicated inhibitors. The supernatants were removed, the cells were rinsed in ice-cold phosphate-buffered saline (PBS), and 500 mL ice-cold buffer (50 mM Tris-HCl pH 7.6, 0.5% Triton X-100, 0.1 mM PMSF, and a protease inhibitor cocktail) was added. Cells were scraped and lysed by shearing 10 times through a 21-gauge needle, then 50 mL of lysate was removed for western blot analysis. Lysates were centrifuged at 330 3 g for 10 min at 4 C and pellets were washed twice in ice-cold PBS and re-suspended in 500 mL PBS. Disuccinimidyl suberate (2mM) was added to the re-suspended pellets, which were incubated at room temperature for 30 min with rotation. Samples were then centrifuged and the cross-linked pellets were re-suspended in 60 mL SDS sample buffer. Samples were boiled for 5 min at 99 C and analyzed by western blotting.
For ASC speck formation, BMDMs were seeded at 5 3 10 5 /mL on chamber slides and allowed to attach overnight. The following day, the cells were primed with LPS and treated with nigericin in the presence or absence of the indicated inhibitors. The cells were fixed in 4% paraformaldehyde followed by ASC and DAPI staining.
Small-interfering RNA Transfection
Peritoneal macrophages were plated in 12-well plates (3 3 10 5 cells per well) and then transfected with 100 nM siRNA using Lipofectamine RNAiMAX (Thermo Fisher Scientific) according to the manufacturer's instructions. The siRNA sequences for mouse SCAP (#1: 5 0 -CCAUGGCGACAUUACCUUGUA-3 0 ; #2: 5 0 -GCGUACAUCCAACAGAUAUUU-3 0 ), SREBP2 (#1:5 0 -GCGGACAACACACAAU AUCAU-3 0 ; #2: 5 0 -GAUGCUACAGUUUGUCAGCAA-3 0 ), S1P (#1: 5 0 -CGGUACUCCAAAGUUCUUGAA-3 0 ; #2: 5 0 -GCCUAUCUAC UAUGGAGGAAU-3 0 ), S2P (#1: 5 0 -GCAGCUAUUAGGGAACAAGUU-3 0 ; #2: 5 0 -CCAGUGAUUGUGGAGACAUUU-3 0 ; #3: 5 0 -GCGG AAAGCAAGGAUGCUU-3 0 ; #4: 5 0 -GGAUUGUCCCGUUACUAAT-3 0 ) and the indicated scrambled siRNAs were chemically synthesized by Genepharma Co., Shanghai, China.
Cellular Fractionation
Cytosol and mitochondria were isolated from THP-1 cells stably overexpressing V5-SCAP using a Mitochondria and Cytosol fractionation Kit (K256; Biovision) according to the manufacturer's guidelines. Isolation of the Golgi apparatus was performed using a Golgi isolation kit (GL0010; Sigma-Aldrich) according to the manufacturer's protocol.
Quantitative PCR RNA was extracted using RNAiso Plus reagent (Takara). Complementary DNA was synthesized with Oligo-dT primer using the SuperScript First-Strand cDNA Synthesis kit (Vazyme Biotech) according to the manufacturer's protocols. Quantitative PCR was performed using SYBR Green Total Cholesterol Assessment Macrophages were lysed with RIPA buffer. Fifty microliters of lysate was transferred to a dark-walled, clear-bottom 384-well dish and then incubated with 50 mL cholesterol detecting reagent-Amplex Red (Invitrogen) for 30 min at 37 C. Fluorescence intensity was measured by a microplate reader.
Immunofluorescence Staining and Confocal Microscopy
Under transient low-expression conditions, HEK293T cells were transfected with 100 ng plasmid as indicated for 12 hr, and stimulated with 10 mM Nigericin for 30 min. BMDMs were stained for 30 min at 37 C with 400 nM Mitotracker Deep Red (Invitrogen). After washing twice with PBS, the cells were fixed in 4% paraformaldehyde in PBS for 20 min and then washed three times in PBS with Tween 20 (PBST). After permeabilization with Triton X-100 and blocking with 5% bovine serum albumin in PBS, the cells were incubated with primary antibodies overnight at 4 C. After washing with PBST, the cells were incubated with secondary antibodies (Sigma) in PBS for 30 min and rinsed in PBST. Analyses were carried out using a Nikon A1R confocal microscope.
Super-resolution Microscopy and Structured Illumination Microscopy
Sample preparation was as described above. For three-dimensional reconstruction, images of BMDMs were captured using NikonStructured Illumination Microscopy (N-SIM); the microscope was an ECLIPSE Ti and the objective lens was a CFI Apochromat TIRF 100XH. Images were recorded as vertical z stacks and processed using NIS analysis and Imaris 8.4 software to generate threedimensional images and movies.
Proximity Ligation Assay
Proximity ligation assays were performed using Duolink reagents (Sigma) according to the manufacturer's instructions.
Virus Transduction of THP1 and J774.1 Macrophages THP1 macrophages were spinfected with retrovirus encoding Flag-SREBP2 or lentivirus encoding V5-SCAP for 90 min at 2500 rpm and 32 C. Forty-eight hours after infection, the cells were selected by culture with 2 mg/mL puromycin (Sigma) or blasticidin (Invivogen). The shRNAs targeting SCAP and SREBP2 were from Sigma. J774.1-shSCAP and THP-1-shSREBP2 cells were also generated by spinfection and selected with puromycin.
ELISA
Supernatants from cell cultures and sera were collected and the concentrations of IL-1b, IL-18, and TNFa (all from eBioscience) were determined according to the manufacturer's instructions.
Liposomal-Cholesterol Preparation
Briefly, 5.8 mg cholesterol and 8 mg PC were placed in chloroform, and a thin film were prepared; subsequently, it was placed in 1 mL RPMI-1640 medium and was sonicated at 4 C.
Sterol-Depletion Experiments
For in vitro experiments, BMDMs were cultured in DMEM supplemented with 10% lipoprotein-deficient serum (LPDS, Sigma), 10 mM lovastatin, and 50 mM mevalonate for 16 hr. Then the cells were primed with LPS and stimulated with nigericin. For in vivo experiment, C57BL/6 mice at 6 weeks of age were fed with a normal chow diet or a chow diet supplemented with 0.2% (wt/wt) lovastatin for 4 days. On day 5, the mice were challenged with LPS or alum.
In Vivo LPS Challenge C57BL/B6 mice were injected intraperitoneally with LPS (20 mg/kg body weight) alone or LPS plus betulin (30 mg/kg), fatostatin (20 mg/kg), desmosterol (30 mg/kg), or 25-HC (50 mg/kg). After 4 hr the mice were killed, and the serum concentrations of IL-1b, IL-18, and TNFa were measured by ELISA.
Alum-Induced Peritonitis
To create peritonitis models, mice were injected intraperitoneally with 2 mg alum dissolved in 0.2 mL sterile PBS; 6 hr later, the mice were killed and the peritoneal cavity washed with cold PBS. The peritoneal lavage fluid was analyzed using FACS Calibur for the recruitment of polymorphonuclear neutrophils with the neutrophil markers Ly6G (RB6-8C5, ebioscience) and CD11b (M1/70, ebioscience), and IL-1b production was determined by ELISA.
QUANTIFICATION AND STATISTICAL ANALYSIS
The results are expressed as the mean ± SD. Statistical analysis was carried out using Student's t test for two groups or the KaplanMeier method for mouse survival as indicated using GraphPad Prism, unless otherwise noted. Differences were considered significant when *p % 0.05, **p % 0.01, ***p % 0.001.
